ArticleNature communications2020
Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer's disease.
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 348 citations in OpenAlex.
- From Design to Bedside: Brain-Targeted Engineered Nanoparticles and Predictive Modeling for Neurodegenerative Diseases Therapeutics.Pharmaceutical research · 2026Review
- Computationally guided design of bioactive nanostructures for targeted clearance of amyloid-β aggregates in Alzheimer's disease.Nature nanotechnology · 2026Article
- Advances and Prospects of Chiral Plasmonic Nanomaterials in Emerging Applications.Nanomaterials (Basel, Switzerland) · 2026Review
- Clinical innovations and future directions of nanoparticles in the treatment of psychiatric and neurological disorders.Molecular psychiatry · 2026Review
- Chiral Titanium Dioxide Nanoparticles Induce Breast Cancer Lung Metastasis.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Gold Nanoparticles in Central Nervous System Diseases: Recent Progress, Challenges, and Therapeutic Opportunities.Nano letters · 2026Review
- Hypothalamic wars: the last nanodelivery.Reviews in endocrine & metabolic disorders · 2026Review
- Advances in Strategies to Transport Nanoparticles Across the Blood-Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer's Disease.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Chiral metal nanozyme-enabled SOD2 activation and siRNA delivery cooperatively mitigating chronic heart failure.Bioactive materials · 2026Article
- Smart Drug-Delivery Approaches for Enhanced Management of Comorbid Conditions in Alzheimer's Disease.Life (Basel, Switzerland) · 2026Review
- Atomically Precise Clusterzymes: A Programmable Optoelectronic Platform for Neuroscience.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The therapeutic efficacy of nanoparticles in the treatment of alzheimer's disease.Acta neurologica Belgica · 2026Review
- Article
- Toward nanomedicine-enabled RNA therapeutics for Alzheimer's disease.Molecular neurodegeneration advances · 2026Review
- The Eco-Friendly Preparation of Se, Zn, and Ag MONPs and Their Current Medical Applications and Drug Delivery for AD Diseases.TheScientificWorldJournal · 2026Review
- Low-Dimensional Nanomaterials in Alzheimer's Disease: Current Applications.Current Alzheimer research · 2026Review
- Trends in Nanoparticle-based Strategies for the Management of Neuroinflammation.CNS & neurological disorders drug targets · 2026Review
- Nanomaterials: an overview of current trends and future prospects in neurological disorder treatment.Journal of translational medicine · 2025Review
- Systemic administration of gold nanoparticles attenuates anxiety-related behaviors and enhances spatial learning performance in rats.IBRO neuroscience reports · 2025Article
- Medical importance and pharmacokinetics of gold nanoparticles in the human body.Molecular cancer · 2025Review
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 2 countries.
Funding
Abstract
Preventing aggregation of amyloid beta (Aβ) peptides is a promising strategy for the treatment of Alzheimer's disease (AD), and gold nanoparticles have previously been explored as a potential anti-Aβ therapeutics. Here we design and prepare 3.3 nm L- and D-glutathione stabilized gold nanoparticles (denoted as L3.3 and D3.3, respectively). Both chiral nanoparticles are able to inhibit aggregation of Aβ42 and cross the blood-brain barrier (BBB) following intravenous administration without noticeable toxicity. D3.3 possesses a larger binding affinity to Aβ42 and higher brain biodistribution compared with its enantiomer L3.3, giving rise to stronger inhibition of Aβ42 fibrillation and better rescue of behavioral impairments in AD model mice. This conjugation of a small nanoparticle with chiral recognition moiety provides a potential therapeutic approach for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.